Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-11/TPO + eltrombopag with sequential MSC infusion in refractory/recurrent thrombocytopenia
ChiCTR2000041323Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Apr 2021
- Modality
- Small Molecules, Hormones & Growth Factors → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of eltrombopag, oprelvekin, thrombopoietin and mesenchymal stem cells in Refractory immune thrombocytopenia (RITP) (2 arms), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Changes of platelet count and function. Started Apr 2021; status: recruiting.
02
Drugs
eltrombopagoprelvekinthrombopoietinmesenchymal stem cells
03
Conditions
Refractory immune thrombocytopenia (RITP)
Beyond the preview
Go deeper on ChiCTR2000041323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041323.